GHRP-6 Testing Helps Diagnose Ectopic ACTH Production by a Lung Tumor
GHRP-6 stimulation testing helped characterize ectopic ACTH syndrome from lung carcinoid by showing preserved GH response alongside ectopic ACTH production — using GH peptide testing for cancer endocrine diagnosis.
Quick Facts
What This Study Found
GHRP-6 stimulation in ACTH-dependent Cushing's from lung carcinoid showed preserved GH response with ectopic ACTH source characteristics, demonstrating GH secretagogue testing utility for diagnosing ectopic versus pituitary ACTH production in Cushing's syndrome.
Key Numbers
How They Did This
case-report study on ghrp, cancer.
Why This Research Matters
Relevant for ghrp, cancer, hormone-optimization.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding GHRP-6 stimulation in ACTH-dependent Cushing's from lung carcinoid showed preserved GH response with ectopic ACTH source characteristics, demonstratin
- Evidence Grade:
- preliminary evidence.
- Study Age:
- Published in 2007.
- Original Title:
- In vivo response to growth hormone-releasing peptide-6 in adrenocorticotropin-dependent Cushing's syndrome by lung carcinoid tumor is associated with growth hormone secretagogue receptor type 1a mRNA expression.
- Published In:
- Journal of endocrinological investigation, 30(4), 334-40 (2007)
- Authors:
- Machado, M C, Sá, S V, Goldbaum, T S, Catania, M, Campos, V C, Corrêa-Giannella, M L, Giannella-Neto, D, Salgado, L R
- Database ID:
- RPEP-01265
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
What was studied?
GHRP-6 Testing Helps Diagnose Ectopic ACTH Production by a Lung Tumor
What was found?
GHRP-6 stimulation testing helped characterize ectopic ACTH syndrome from lung carcinoid by showing preserved GH response alongside ectopic ACTH production — using GH peptide testing for cancer endocrine diagnosis.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01265APA
Machado, M C; Sá, S V; Goldbaum, T S; Catania, M; Campos, V C; Corrêa-Giannella, M L; Giannella-Neto, D; Salgado, L R. (2007). In vivo response to growth hormone-releasing peptide-6 in adrenocorticotropin-dependent Cushing's syndrome by lung carcinoid tumor is associated with growth hormone secretagogue receptor type 1a mRNA expression.. Journal of endocrinological investigation, 30(4), 334-40.
MLA
Machado, M C, et al. "In vivo response to growth hormone-releasing peptide-6 in adrenocorticotropin-dependent Cushing's syndrome by lung carcinoid tumor is associated with growth hormone secretagogue receptor type 1a mRNA expression.." Journal of endocrinological investigation, 2007.
RethinkPeptides
RethinkPeptides Research Database. "In vivo response to growth hormone-releasing peptide-6 in ad..." RPEP-01265. Retrieved from https://rethinkpeptides.com/research/machado-2007-in-vivo-response-to
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.